Prognosis and reevaluation of lung cancer by positron emission tomography imaging

Jeremy J. Erasmus, Eric Rohren, Stephen G. Swisher

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Positron emission tomography (PET) imaging using 18F-2-deoxy-D- glucose, a D-glucose analog labeled with fluorine-18 (FDG-PET), is being evaluated in the assessment of prognosis and therapeutic response in patients with non-small cell lung cancer. FDG-PET imaging has the potential to allow more appropriate selection of patients for surgical resection and for neoadjuvant and aduvant chemotherapy as well as chemoradiation. Currently, the absence of standardization in how FDG-PET images are obtained and interpreted limits its widespread clinical utility. Although prospective multi-institutional trials and standardization of FDG-PET imaging protocols are required for the true utility to be determined, the evolving experience with FDG-PET imaging indicates a greater and integral role in treatment decisions. This article will discuss the assessment of prognosis and treatment response in patients with non-small cell lung cancer using FDG-PET, and will emphasize potential advantages and limitations in clinical management.

Original languageEnglish (US)
Pages (from-to)171-179
Number of pages9
JournalProceedings of the American Thoracic Society
Volume6
Issue number2
DOIs
StatePublished - Apr 15 2009

Keywords

  • Lung cancer
  • PET-CT
  • Response

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Prognosis and reevaluation of lung cancer by positron emission tomography imaging'. Together they form a unique fingerprint.

Cite this